European Case Law Identifier: | ECLI:EP:BA:2012:R001611.20120323 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 23 March 2012 | ||||||||
Case number: | R 0016/11 | ||||||||
Petition for review of: | T 1710/09 | ||||||||
Application number: | 01201913.9 | ||||||||
IPC class: | A61K 31/663 | ||||||||
Language of proceedings: | EN | ||||||||
Distribution: | B | ||||||||
Download and more information: |
|
||||||||
Title of application: | Alendronate for use in the treatment of osteoporosis | ||||||||
Applicant name: | Merck Sharp & Dohme Corp. | ||||||||
Opponent name: | PLIVA, Farmaceutska Industrija Dionicko Drustvo + AWD.pharma GmbH & Co. KG STADA Arzneimittel AG Hexal AG + Sandoz AG Arrow International Ltd. betapharm Arzneimittel GmbH ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Gedeon Richter Plc. Generics [UK] Ltd. et al STADA Arzneimittel GmbH "Interpharm" ProduktionsgmbH BIOGARAN Tecnimede, Sociedade Tecnico-Medicinal, S.A. ACTAVIS GROUP |
||||||||
Board: | EBA | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | New objection raised by the Board (no)- denial of the right to be heard (no)- petition for review clearly unallowable | ||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/r110016eu1.html
Date retrieved: 17 May 2021